Related references
Note: Only part of the references are listed.Enzyme replacement therapy for mild patients with Gaucher disease
Ari Zimran et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Gaucher disease: Resetting the clinical and scientific agenda
Pramod K. Mistry et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Detection of chitinase activity by 2-aminobenzoic acid labeling of chito-oligosaccharides
Karen Ghauharali-van der Vlugt et al.
ANALYTICAL BIOCHEMISTRY (2009)
Increased chitotriosidase activity in serum of leprosy patients: Association with bacillary leprosy
Anand Iyer et al.
CLINICAL IMMUNOLOGY (2009)
Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy
A. Langeveld et al.
BLOOD CELLS MOLECULES AND DISEASES (2008)
Potential artefacts in proteome analysis of plasma of Gaucher patients due to protease abnormalities
Marielle J. van Breemen et al.
CLINICA CHIMICA ACTA (2008)
Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease
Karen Ghauharall-van der Vlugt et al.
CLINICA CHIMICA ACTA (2008)
A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome
Andrea Balreira et al.
HUMAN MOLECULAR GENETICS (2008)
Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit
Max A. Seibold et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Chitotriosidase activity in juvenile idiopathic arthritis
Juergen K. H. Brunner et al.
RHEUMATOLOGY INTERNATIONAL (2008)
Non-neuronopathic Gaucher disease due to saposin C deficiency
Anna Tylki-Szymanska et al.
CLINICAL GENETICS (2007)
LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-Glucocerebrosidase
David Reczek et al.
CELL (2007)
Human chitotriosidase polymorphisms G354R and A442V associated with reduced enzyme activity
Pauline Lee et al.
BLOOD CELLS MOLECULES AND DISEASES (2007)
Pharmacologic chaperoning as a strategy to treat Gaucher disease
Zhanqian Yu et al.
FEBS JOURNAL (2007)
Type 1 Gaucher disease: Null and hypomorphic novel chitotriosidase mutations - Implications for diagnosis and therapeutic monitoring
Marie E. Grace et al.
HUMAN MUTATION (2007)
Gaucher disease
Terry D. Butters
CURRENT OPINION IN CHEMICAL BIOLOGY (2007)
Increased plasma macrophage inflammatory protein (MIP)-1α and MIP-1β levels in type 1 Gaucher disease
Marielle J. van Breemen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2007)
Assessing the statistical validity of proteomics based biomarkers
Suzanne Smit et al.
ANALYTICA CHIMICA ACTA (2007)
Monitoring of Gaucher patients with a novel chitotriosidase assay
Aricha Schoonhoven et al.
CLINICA CHIMICA ACTA (2007)
Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease
Johannes P. C. Vissers et al.
MOLECULAR & CELLULAR PROTEOMICS (2007)
Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity
Johannes M. Aerts et al.
DIABETES (2007)
HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma
Johanna E. M. Groener et al.
CLINICAL CHEMISTRY (2007)
Comparison between the biochemical properties of plasma chitotriosidase from normal individuals and from patients with Gaucher disease, GM1-gangliosidosis, Krabbe disease and heterozygotes for Gaucher disease
Alessandro Wajner et al.
CLINICAL BIOCHEMISTRY (2007)
Identification of the non-lysosomal glucosylceramidase as β-glucosidase 2
Rolf G. Boot et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Correlation between Gaucher disease clinical severity and surrogate markers is weak - Response
Ari Zimran et al.
BLOOD (2007)
Mutation of β-glucosidase 2 causes glycolipid storage disease and impaired male fertility
Yildiz Yildiz et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Plasma chitotriosidase in male Fabry patients: A marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy
A. C. Vedder et al.
MOLECULAR GENETICS AND METABOLISM (2006)
Limitations in quantitation of the biomarker CCL 18 in Gaucher disease blood samples by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry
Marielle J. van Breemen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2006)
Intrathecal chitotriosidase and the outcome of multiple sclerosis
S. Sotgiu et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A/B and C
Markus Ries et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2006)
CCL18: A urinary marker of Gaucher cell burden in Gaucher patients
Rolf G. Boot et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2006)
Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease
Ari Zimran et al.
BLOOD (2006)
Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels:: a 2-center retrospective analysis
Maaike de Fost et al.
BLOOD (2006)
Substrate reduction therapy of glycosphingolipid storage disorders
Johannes M. F. G. Aerts et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2006)
Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity
M van Eijk et al.
INTERNATIONAL IMMUNOLOGY (2005)
Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease
PB Deegan et al.
BLOOD CELLS MOLECULES AND DISEASES (2005)
Candidate-based proteomics in the search for biomarkers of cardiovascular disease
L Anderson
JOURNAL OF PHYSIOLOGY-LONDON (2005)
Plasma chitotriosidase and CCL18: Early biochemical surrogate markers in type B Niemann-Pick disease
J Brinkman et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2005)
Twin pairs showing discordance of phenotype in adult Gaucher's disease
RH Lachmann et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2004)
Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease
HJ Moller et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis
S Grosso et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2004)
Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages
LA Boven et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2004)
Gaucher disease: complexity in a simple disorder
E Sidransky
MOLECULAR GENETICS AND METABOLISM (2004)
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention
RG Boot et al.
BLOOD (2004)
Biochemical characterization of chitotriosidase enzyme: comparison between normal individuals and patients with Graucher and with Niemann-Pick diseases
A Wajner et al.
CLINICAL BIOCHEMISTRY (2004)
The expanding spectrum of disorders with elevated plasma chitotriosidase activity: An update
H Michelakakis et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2004)
Transglycosidase activity of chitotriosidase - Improved enzymatic assay for the human macrophage chitinase
B Aguilera et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Serum chitotriosidase activity is increased in subjects with atherosclerosis disease
M Artieda et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Crystal structures of allosamidin derivatives in complex with human macrophage chitinase
FV Rao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Plasma chitotriosidase activity in acute Plasmodium falciparum malaria
R Barone et al.
CLINICA CHIMICA ACTA (2003)
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement
TM Cox et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2003)
Structure of human chitotriosidase - Implications for specific inhibitor design and function of mammalian chitinase-like lectins
F Fusetti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Clinically relevant therapeutic endpoints in type I Gaucher disease
CEM Hollak et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2001)
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
T Cox et al.
LANCET (2000)
Share Paper
